TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
RNA

Atrium Therapeutics, Inc.

Healthcare · Biotechnology

7.80$ -3.7% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Atrium Therapeutics, Inc. (RNA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 281 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet RNA
Line item Q4 11 Q4 12 Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
33 62 56 53 131 125 117 106 89 – – – 97 93 355 346 334 315 291 426 428 421 421 431 639 614 611 573 629 951 1,347 1,641 1,564 1,459 1,369 278 278 292 281
– – – – – – – – – 3.1 – – 96 90 354 344 332 312 287 422 411 405 404 414 623 597 595 555 611 934 1,329 1,622 1,542 1,435 1,251 271 273 286 275
24 54 46 40 117 113 107 95 78 -3.1 – – 95 89 352 341 321 301 276 410 320 139 125 144 340 119 154 86 185 471 576 370 220 254 244 270 270 268 73
– – – – – – – – – 3.1 – – 95 89 352 341 328 308 279 413 406 397 398 406 611 586 577 543 595 916 1,299 1,589 1,501 1,380 1,183 270 270 268 264
– – – – – – – – – – – – – – – – 1.2 1.2 1.4 0.9 0.9 0.9 1.1 1.3 2.4 1.0 1.2 1.0 8.6 9.0 16 19 28 37 8.5 15 12 15 –
– – – – – – – – – – – – 0.0 – – – -1.2 0.0 -1.4 -0.9 -0.9 0.0 0.0 0.0 0.0 -1.0 -1.1 -1.0 – – -16 – – – – – – – –
4.0 3.2 3.1 3.0 3.1 3.0 2.7 2.8 2.5 – – – – 1.1 1.3 1.7 1.9 2.5 2.7 3.2 16 15 16 15 15 – 16 – – – – – – – – – – – –
1.2 1.1 1.1 1.0 1.0 1.0 1.0 1.4 1.4 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
29 42 40 43 41 38 19 18 21 – – – 162 27 25 26 28 29 26 31 46 45 46 54 61 55 52 56 128 121 126 137 139 130 176 65 71 58 66
15 16 17 20 18 13 8.0 7.4 10 – – – 10 11 12 14 15 18 16 22 30 31 34 43 52 48 45 49 81 75 84 91 98 85 135 32 42 22 32
– – – – – – – – – – – – 2.8 2.8 – 0.7 2.8 1.0 0.9 0.1 1.8 2.5 3.1 3.1 3.1 3.1 3.2 3.6 3.6 3.7 3.8 3.8 3.8 3.9 3.9 4.0 3.7 2.7 1.7
3.3 3.2 3.6 5.3 3.5 2.6 3.0 2.0 4.0 – – – 2.3 3.5 5.4 6.0 7.7 10 8.5 12 2.8 18 21 26 4.6 3.9 5.7 5.6 8.8 2.3 8.9 7.7 8.5 6.6 3.9 0.5 4.4 0.8 3.5
3.2 8.2 8.2 9.3 9.9 11 11 11 11 – – – 1.8 1.1 – – – – – – – – – – – – – – – – – – – – – – – – –
3.4 21 16 10 91 87 98 87 68 -8.4 – – -65 66 330 320 306 286 264 395 381 376 374 377 578 559 559 517 501 831 1,221 1,503 1,425 1,329 1,193 213 207 234 215
– – – – – – – – – – – – -22 -28 -39 -50 -67 -90 -117 -146 -185 -219 -264 -308 -359 -411 -458 -510 -571 -640 -710 -791 -893 -1,009 -1,166 -1,341 -1,578 12 -8.1
– – – – – – 53 – – 21 21 21 21 31 8.6 37 37 38 38 43 24 48 50 53 57 70 71 74 76 87 107 123 128 129 130 138 17 17 17

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?